Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-03-04
|
BAX 826 (rFVIII - recombinant factor VIII - SHP656) |
hemophilia A |
1 |
Baxalta (USA - IL), now Shire (UK - USA) |
Rare diseases - Genetic diseases - Hematological diseases |
2016-03-04
|
AKN-028 |
acute myeloid leukemia (AML) |
1-2 |
Akinion Pharmaceuticals (Sweden) |
Cancer - Oncology |
2016-03-04
|
vatelizumab |
relapsing remitting multiple sclerosis (RRMS) |
2 |
Genzyme (USA - MA), a Sanofi company |
Autoimmune diseases - Neurodegenerative diseases |
2016-03-04
|
SAR3419 (coltuximab ravtansine) |
non-Hodgkin's lymphoma (NHL) and other B-cell malignancies |
2 |
Immunogen (USA) Sanofi (France) |
Cancer - Oncology |
2016-03-03
|
Keytruda® (pembrolizumab - MK-3475) |
hepatocellular carcinoma |
2 |
Merck&Co (USA - NJ) |
Cancer - Oncology |
2016-03-03
|
PRX-102 (alpha-galactosidase-A) |
Fabry disease |
|
Protalix BioTherapeutics (Israel) |
Rare diseases - Genetic diseases |
2016-03-03
|
Benlysta® (belimumab) |
systemic lupus erythematosus (SLE) |
3 |
GSK (UK) |
Autoimmune diseases |
2016-03-02
|
SBC-103 (rhNAGLU enzyme) |
mucopolysaccharidosis IIIB (Sanfilippo B syndrome) |
1-2 |
Synageva BioPharma (USA - MA), now Alexion Pharmaceuticals (USA - CT) |
Rare diseases - Genetic diseases |
2016-03-02
|
|
coronary artery disease |
|
Regeneron Pharmaceuticals (USA - NY) Geisinger Health System (USA - PA) |
Cardiovascular diseases |
2016-03-02
|
danegaptide |
ischemic reperfusion injury |
2 |
Zealand Pharma (Denmark) |
Cardiovascular diseases |
2016-03-02
|
|
cutaneous T-cell lymphoma (CTCL) |
|
|
Cancer - Oncology |
2016-03-02
|
MRG-106 |
cutaneous T-cell lymphoma (CTCL), mycosis fungoides subtype |
1 |
Miragen Therapeutics (USA - CO) |
Cancer - Oncology - Rare diseases |
2016-03-02
|
MSB11022, a biosimilar version of Humira® (adalimumab) |
moderate to severe chronic plaque psoriasis |
3 |
Merck KGaA (Germany) |
Autoimmune diseases - Dermatological diseases |
2016-03-01
|
aramchol |
HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD) |
2 |
Galmed Pharmaceuticals (Israel) |
Hepatic diseases - Liver diseases |
2016-03-01
|
MSB0011359C (M7824) |
solid tumors |
1 |
Merck KGaA (Germany) |
Cancer - Oncology |
2016-02-29
|
MK-8628 (formerly known as OTX015) |
advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), or castration-resistant prostate cancer (CRPC) |
1 |
Merck&Co (USA - NJ) |
Cancer - Oncology |
2016-02-29
|
MK-8628 (formerly known as OTX015) |
acute myeloid leukemia (AML) Including AML de Novo and AML secondary to myelodysplastic syndrome (MDS) and in participants with diffuse large B cell lymphoma (DLBCL). |
1 |
Merck&Co (USA - NJ) |
Cancer - Oncology |
2016-02-26
|
PM184 |
advanced breast cancer, hormone-receptor positive,HER2-negative, locally advanced and/or metastatic breast cancer |
2 |
PharmaMar (Spain) |
Cancer - Oncology |
2016-02-25
|
ABX464 |
HIV/Aids |
2a |
Abivax (France) |
Infectious diseases |
2016-02-25
|
BLZ-100 - chlorotoxin conjugated to indocyanine green dye |
head and neck squamous cell carcinoma |
preclinical |
Blaze Biosciences (USA - WA) |
Cancer - Oncology |